4//SEC Filing
Gallagher Kathleen P. 4
Accession 0001599901-25-000097
CIK 0001599901other
Filed
May 1, 8:00 PM ET
Accepted
May 2, 7:55 PM ET
Size
9.3 KB
Accession
0001599901-25-000097
Insider Transaction Report
Form 4
Gallagher Kathleen P.
Chief Program Officer
Transactions
- Sale
Common Stock
2025-05-01$32.40/sh−5,875$190,324→ 50,554 total - Exercise/Conversion
Common Stock
2025-05-01$16.65/sh+5,875$97,819→ 56,429 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-05-01−5,875→ 28,471 totalExercise: $16.65Exp: 2032-07-17→ Common Stock (5,875 underlying)
Footnotes (3)
- [F1]This option exercise and sale was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 12, 2024.
- [F2]This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.99. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option was granted on July 18, 2022 and vests in equal installments of 1/48 of the original number of shares subject to the option on each monthly anniversary of such grant date, until it is fully vested and exercisable on July 18, 2026.
Documents
Issuer
Avidity Biosciences, Inc.
CIK 0001599901
Entity typeother
Related Parties
1- filerCIK 0002048409
Filing Metadata
- Form type
- 4
- Filed
- May 1, 8:00 PM ET
- Accepted
- May 2, 7:55 PM ET
- Size
- 9.3 KB